L26/P-674 Clinical utility and efficiency of abnormally fertilized oocytes derived blastocysts in PGT-M cycles
Human Reproduction · 01.07.2026 · 41 (Supplement_1)
DOI: 10.1093/humrep/deag083.1004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von I. De Croo und 11 weiteren Autor:innen.
Abstract (Originalsprache)
Study question What is the clinical utility and diagnostic efficiency of blastocysts derived from abnormally fertilized oocytes (AFOs) in PGT-M cycles? Summary answer Testing AFO derived blastocysts has low overall clinical efficiency but may prevent cycles without an embryo available for transfer in selected PGT-M cycles. What is known already Abnormally fertilized oocytes (AFOs), including 1pn, 2.1pn and ≥3pn zygotes, were historically discarded because of a presumed high risk of chromosomal abnormalities. Accumulating evidence indicates that a substantial proportion of AFO derived blastocysts are diploid. Healthy live births following transfer of diploid AFO derived embryos have been reported. In PGT-M cycles, where unaffected embryos may be scarce, AFO derived embryos may represent an important additional resource. Nevertheless, clinical implementation remains limited and heterogeneous across centers. Study design, size, duration This single-center retrospective cohort study included PGT-M cycles with ovum pick-up (OPU) (n = 387) performed from October 2024 until November 2025. Since October 2024 AFOs were routinely cultured to blastocyst and underwent trophectoderm biopsy if eligible. Primary outcome measures were the proportion of AFO derived embryos eligible for transfer after comprehensive PGT-M. Secondary outcomes included fertilization rate, blastocyst development, biopsy eligibility and clinical outcomes following transfer of AFO derived blastocysts. Follow-up continued until January 15, 2026. Participants/materials, setting, methods All consecutive PGT-M cycles performed at a tertiary fertility center were reviewed. Cycles without mature oocytes and those involving translocation carriers were excluded. Intracytoplasmic sperm injection was performed and embryos were cultured untill day 5 or 6 in a time lapse incubator (Embrysoscope, Vitrolife). AFO derived embryos were cultured to the blastocyst stage, underwent trophectoderm biopsy and analyzed using comprehensive PGT-M, including ploidy assessment, parental origin and analysis of their monogenic disease status. Main results and the role of chance In total, 387 PGT-M cycles with OPU were included. The mean number of cumulus-oocyte-complexes per OPU was 14.2, with a mean of 11.3 mature (MII) oocytes. Of 4,353 injected MII oocytes, 3,471(79.7%) showed normal fertilization (2pn). Abnormal fertilization occurred in 223 oocytes: 117 (2.7%) 1pn, 7 (0.16%) 2.1pn, 94 (2.2%) 3pn and 5 (0.11%) >3pn. Blastocyst development eligible for trophectoderm biopsy occurred in 15 (12.8%) 1pn, 3 (42.9%) 2.1pn, 28 (29.8%) 3pn and 1 (20.0%) >3pn derived embryos, compared with 54.6% of normally fertilized embryos. In total 47 AFO derived blastocysts underwent comprehensive PGT-M. Of these 3 (6.3%) were deemed transferable, defined as unaffected by the monogenic condition and diploid, corresponding to a number-needed-to-test of 16 AFO derived blastocysts to identify one transferable embryo. These comprised two blastocysts derived from 1pn zygotes and one from a 2.1pn zygote. Regardless of their monogenic disease status, diploidy was observed in 60.0% (9/15) of 1pn and 66.7% (2/3) of 2.1pn zygote derived blastocysts, compared with 0% (0/28) of 3pn zygote derived blastocysts. The only >3pn zygote derived blastocyst showed complex aneuploidy. Transfer of one 1pn-zygote derived blastocyst resulted in an ongoing pregnancy, representing the patient’s only embryo available for transfer. Limitations, reasons for caution Few AFO derived embryos were diploid and not affected by the monogenic condition and only one had been transferred at the time of analysis, limiting conclusions on implantation and live birth rates. The retrospective design, relative small number of AFO derived blastocysts and single-center setting may restrict generalizability. Wider implications of the findings Selective inclusion of AFO derived blastocysts, particularly those from 1pn and 2.1pn zygotes may offer clinical utility in PGT-M cycles lacking transferable embryos. Although clinically rather inefficient, this approach may help prevent cycle cancellation in selected patients. Large prospective studies are needed to confirm clinical safety and reproductive outcomes. Trial registration number No
Zitieren
APA
Croo, I. D., Jalali, R., Baetens, M., Dhaenens, L., Symoens, S., Menten, B., Peters, N., Kumps, C., Stoop, D., Janssens, S., Tilleman, K., & Meerschaut, F. V. (2026). L26/P-674 Clinical utility and efficiency of abnormally fertilized oocytes derived blastocysts in PGT-M cycles. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.1004
Vancouver
Croo ID, Jalali R, Baetens M, Dhaenens L, Symoens S, Menten B, et al. L26/P-674 Clinical utility and efficiency of abnormally fertilized oocytes derived blastocysts in PGT-M cycles. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.1004
BibTeX
@article{Croo2026,
author = {Croo, I. De and Jalali, R. and Baetens, M. and Dhaenens, L. and Symoens, S. and Menten, B. and Peters, N. and Kumps, C. and Stoop, D. and Janssens, S. and Tilleman, K. and Meerschaut, F. Vanden},
title = {L26/P-674 Clinical utility and efficiency of abnormally fertilized oocytes derived blastocysts in PGT-M cycles},
journal = {Human Reproduction},
year = {2026},
volume = {41},
number = {Supplement_1},
doi = {10.1093/humrep/deag083.1004}
}
EUVIMED